Sumitomo Mitsui DS Asset Management Company Ltd Has $72.32 Million Holdings in AbbVie Inc. $ABBV

Key Points

• Sumitomo Mitsui DS Asset Management boosted its stake in AbbVie by 10.5% in Q4 to 316,523 shares, valued at approximately $72.32 million.
• AbbVie beat Q1 estimates (EPS $2.65 vs. $2.59) with revenue of $15 billion, up 12.4%, which lifted guidance and investor attention even as the stock traded near $206.
• AbbVie announced a quarterly dividend of $1.73 (annualized $6.92, yield ~3.4%) despite a very high payout ratio (340.89%), and analysts have a consensus rating of "Moderate Buy" with a $252.90 target.

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 10.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 316,523 shares of the company's stock after buying an additional 30,032 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in AbbVie were worth $72,322,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ABBV. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Vanguard Group Inc. increased its holdings in shares of AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Raymond James Financial Inc. increased its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Alliancebernstein L.P. increased its holdings in shares of AbbVie by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock valued at $1,685,918,000 after purchasing an additional 1,758,657 shares during the period. Finally, Amundi increased its holdings in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Stock Down 1.0%

Shares of ABBV stock opened at $206.12 on Wednesday. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81. The firm has a market cap of $364.46 billion, a PE ratio of 101.54, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32. The stock has a 50 day moving average of $214.17 and a 200-day moving average of $221.34.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the company earned $2.46 earnings per share. The company's quarterly revenue was up 12.4% compared to the same quarter last year. As a group, equities analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Evercore dropped their target price on AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a report on Wednesday, February 4th. Piper Sandler lowered their price target on AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a research note on Thursday, April 23rd. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Finally, Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research note on Tuesday, January 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and a consensus target price of $252.90.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.